Mass Gen Cooley Dickinso	eral Brigham on Hospital		(Patient Sticker)
	PHYSICIAN ORDER SET : ANIFROLUMAB		
CDH 208-274	Page 1 of 3		-
Patient:		DOB:	Gender:
Patient Phone #:		Height:	Weight:
Diagnosis:		ICD-10 Code:	
Treatment Start Date	:		
Provider Facility Name:		Provider Facility Ac	ddress:
Ordering Provider:		Date:	
Signature:			

Complete, Sign, and fax this document to: CDH Central Scheduling at 413-582-2183

\*\*Please include H&P/current medications list/allergies, and ensure that med authorizations have been obtained\*\*

Anifrolumab is indicated for moderate to severe SLE in adult patients when all of the following criteria are met: By signing above, there is a diagnosis of moderate to severe SLE, without severe active central nervous system lupus or severe active lupus nephritis.

## Nursing Communication

	Interval	Defer Until	Duration
Routine. Starting when released. Anifrolumab is not recommended in combination with other biologic therapies. Consult ordering provider if another biologic is ordered and patient is receiving.	Every visit		Until discont'd
Medications			
	Interval	Defer Until	Duration
<ul> <li>anifrolumab-fnia (SAPHNELO) 300 mg in sodium chloride 0.9%</li> <li>100 mL IVPB</li> </ul>	Every 4 weeks		Until discont'd

300 MG. Intravenous. Administer over 30 minutes. Once. Starting at treatment start time. For 1 dose. Administer using a sterile, low-protein binding 0.2 or 0.22 micron in-line filter. After infusion is completed, flush line with 25 mL of NS. PROTECT FROM LIGHT.



Cooley Dickinson Ho	spital	
	PHYSICIAN ORDER SET : ANIFROLUMAB	
CDH 208-274	Page 2 of 3	

(Patient Sticker)

Labs

	Interval	Defer Until	Duration
□ CBC and Differential	Every 12 weeks		Until discont'd
Routine, Once, Starting once when released			
□ Comprehensive Metabolic Panel (CMP)	Every 12 weeks		Until discont'd
Routine, Once, Starting when released			
Complement C3	Every 12 weeks		Until discont'd
Routine, Once, Starting when released			
Complement C4	Every 12 weeks		Until discont'd
Routine, Once, Starting when released.,			
Double-Stranded DNA Antibodies	Every 12 weeks		Until discont'd
Routine, Once, Starting Once, Starting when release,			

## **Catheter Management**

		Interval	Defer Until	Duration	
	Line Access	PRN		Until discont'd	
	Routine, Once, Starting S For 1 Occurrences, As needed. Starting when release	ed. Until Specified.			
	Insert peripheral IV, or access peripheral, or central venous access device, to p	rovide treatment.			
	alteplase (CATHFLO) 1 mg/mL injection 2 mg	PRN		Until discont'd	
	2 mg, Intracatheter, As needed, line care, For central venous access device req repeat once per lumen, Starting S	uiring clearance. Adm	iinister per institution	al guidelines. May	
	lidocaine-prilocaine (EMLA) cream	PRN		Until discont'd	
Topical, As needed, pre procedure/treatment, Apply prior to the PIV insertion or port access, Starting S					
	heparin 100 units/mL flush 5 mL	PRN		Until discont'd	
	5 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting S				
	heparin 10 units/mL flush 3 mL	PRN		Until discont'd	
	3 mL, Intravenous, As needed, line care, Line care per institutional guidelines, S	itarting S			
	heparin 10 units/mL flush 5 mL	PRN		Until discont'd	
	5 mL, Intravenous, As needed, line care, Line care per institutional guidelines, S	tarting S			
	heparin 1000 units/mL flush 2 mL	PRN		Until discont'd	
	2 mL, Intracatheter, As needed, line care, APHERESIS LINE CARE ONLY per i FROM EACH LUMEN PRIOR TO FLUSHING OR INFUSING THROUGH THE			THDRAWN	
	sodium chloride (NS) 0.9 % syringe flush 3 mL	PRN		Until discont'd	
	3 mL, Intravenous, As needed, line care, Line care per institutional guidelines, S	tarting S			
	sodium chloride (NS) 0.9 % syringe flush 10 mL	PRN		Until discont'd	
	10 mL, Intravenous, As needed, line care, Line care per institutional guidelines,	Starting S			
	sodium chloride (NS) 0.9 % syringe flush 20 mL	PRN		Until discont'd	
	20 mL, Intravenous, As needed, line care, Line care per institutional guidelines,	Starting S			
	sodium chloride 0.9% infusion	PRN		Until discont'd	
	20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open t	o provide treatment, S	Starting S		
	D5W infusion	PRN		Until discont'd	
	20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open t	o provide treatment, S	Starting S		



## 📻 Mass General Brigham

	Cooley Dickinson Hospita	1				
		YSICIAN ORDER SET : NIFROLUMAB				
CD	0H 208-274	Page 3 of 3		_		
Emerg	gency Medications					
	<u> </u>		Ir	nterval	Defer Until	Duration
	Provider and Nurse Con	munication		RN	Deler Until	Until discont'd
	Routine, Until discontinued, Sta	arting S, Treatment of SEVERE reac	tion (ANAPHYLAXIS):	hypotensio	n, throat swelling, wh	eezing, respiratory
	administer oxygen as needed, indicated.	saturation. Stop the infusion and trea monitor vital signs and proceed with	administering adjunct	HYPERSE	NSITIVITY medication	ns as clinically
	<b>EPINEPHrine injection 0</b>	.3 mg	P	RN		Until discont'd
		led, anaphylaxis, Administer FIRST	for anaphylaxis. May r	epeat times	1 dose, Starting S	
	For 2 doses. Pharmacy's	Suggested Dose Instructions; Epine	phrine 1:1000 is equiv	alent to 1 m	ng/mL	
	sodium chloride 0.9% be	olus 1,000 mL	Р	RN		Until discont'd
	1,000 mL, Intravenous, Once a	s needed, other (free text field), For	hypotension, Starting	S, For 1 Do	ses	
	Oxygen Therapy - Non-F	Rebreather	P	'RN		Until discont'd
_	Routine					
	Select a Mode of Therapy: Nor	a-Rebreather				
Hyper	rsensitivity					
	,		L	to much	Defenduntil	Duration
	Provider and Nurse Con	munication		nterval RN	Defer Until	Duration Until discont'd
		arting S For Until specified, Treatmer			tion: Stop the infusion	
	and emergency personnel, adm	ninister oxygen as needed, monitor v action, refer to Emergency Medicatic	vital signs and proceed			
	albuterol nebulizer solut	tion 2.5 mg	P	RN		Until discont'd
	2.5 mg, Nebulization, Once as	needed, shortness of breath, wheez	ing, wheezing, shortne	ess of breath	h, Starting S, For 1 Do	oses
	acetaminophen (TYLEN	OL) tablet 975 mg	Р	RN		Until discont'd
	975 mg, Oral, Once as needed	, fever, Starting S, For 1 Doses				
	diphenhydrAMINE (BEN	ADRYL) injection 25 mg	Р	'RN		Until discont'd
		l, itching, itching, hives. Begin with 2	5 mg. If patient has co	ntinued rea	ction, administer add	tional 25 mg,
	famotidine (PEPCID) inje	ection 20 mg	Р	RN		Until discont'd
		eeded, other (free text field), Adjunc	t treatment for mild-mo	oderate, or S	SEVERE reaction Hol	
	cetirizine (ZyrTEC) table	t 10-20 mg	Р	RN		Until discont'd
		ed, allergies, Adjunct treatment for m	nild-moderate, or SEVE	ERE reactio	n, Starting S, For 1 D	oses
	HOLD IF giving fexofenadine.					
	fexofenadine (ALLEGRA	A) tablet 90-180 mg	P	'RN		Until discont'd
	-	ded, allergies, Adjunct treatment for	mild-moderate, or SEV	/ERE reacti	on, Starting S, For 1 I	
	HOLD IF giving cetirizine.					
	methylprednisolone sod	lium succinate (SOLU-Med	rol) IV 40 ma P	'RN		Until discont'd
		eeded, other (free text field), Adjunc			SEVERE reaction, Sta	
	ondansetron (ZOFRAN)	injection 4 mg	Р	RN		Until discont'd
	· · · ·	nausea, vomiting, may repeat x 1 de				
	meperidine (DEMEROL)		-	'RN		Until discont'd
	• • •	eeded, rigors, Starting S, For 1 Dose				5 alooont u
versio	n 11/2024					

(Patient Sticker)